西维斯健康(CVS)
搜索文档
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 10, 2024 in CVS Health Corporation Lawsuit – CVS
GlobeNewswire News Room· 2024-08-08 01:21
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS). Shareholders who purchased shares of CVS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cvs-health-corporation-loss-submission-form-2/?id=94057&from=3 CLASS PERIOD: Ma ...
CVS Health(CVS) - 2024 Q2 - Earnings Call Transcript
2024-08-08 00:06
财务数据和关键指标变化 - 第二季度收入约911亿美元,同比增长2.6% [10][33] - 调整后营业利润超过37亿美元 [10] - 上半年经营活动产生的现金流约80亿美元,同比有所下降,主要由于Medicare付款时间和Medicare使用率的影响 [33] 各条业务线数据和关键指标变化 医疗保险业务 - 第二季度收入约325亿美元,同比增长超过21% [34] - 医疗会员人数近2700万,环比增加20万 [34] - 医疗保险利润率89.6%,同比上升340个基点,主要受Medicare Advantage利用率上升、2024年支付年度星级评级下降、Medicaid人群重症程度上升以及2023年个人交易所风险调整估计变更的影响 [35][38][39] - 预计2024年全年医疗保险利润率将在90.6%-90.8%之间,较之前指引上升80-100个基点 [51] - 2025年Medicare Advantage业务有望实现100-200个基点的利润率改善 [20][60] - 2025年商业业务预计将实现会员增长,保留率维持在高90%水平 [21] 药品与消费者健康业务 - 第二季度收入约298亿美元,同比增长3.7% [45] - 调整后营业利润约12亿美元,同比有所下降,主要受药品报销压力、前店销量下降以及与Medicare相关的某些付款时间的影响 [46] - 同店药房销售额同比增长超过9%,同店处方量增长6.5%,零售药房市场份额达到27.2%创新高 [47] - 同店前店销售额同比下降约4%,剔除OTC检测试剂盒影响后下降约2%,反映了消费需求的普遍疲软 [48] 健康服务业务 - 第二季度收入约422亿美元,同比下降约9%,主要受之前宣布失去一大客户以及持续的药品客户价格改善的影响 [42] - 调整后营业利润约19亿美元,同比增长超过1%,反映了采购经济性改善,部分被持续的药品客户价格改善和失去大客户所抵消 [43] - 第二季度处理的总处方量约4.71亿个,会员总数约9000万 [43] - Signify和Oak Street业务表现强劲,收入同比分别增长27%和32% [44] 公司战略和发展方向及行业竞争 - 公司正在推进创新的药品定价模式,包括CVS CostVantage和CVS Caremark TrueCost,以提高定价透明度和简单性 [14][15][104][105][123] - 生物类似药业务Cordavis为客户带来近4亿美元的净节省 [16] - 公司启动了多年期生产力提升计划,预计到2025年可实现超过5亿美元的利润增长 [17][81] - 公司正在加快整合医疗服务资产,如Signify和Oak Street,与Aetna、MinuteClinic和CVS Pharmacy等资产进行协同 [28][29] - 公司对FTC关于PBM行业的中期报告持有不同意见,认为PBM在降低药价方面发挥了关键作用 [26][117][118][119][120][121][124][125] 管理层对经营环境和未来前景的评论 - 医疗保险业务2024年表现未达预期,公司决定进行管理层变更,由CEO Karen Lynch和CFO Tom Cowhey直接接管该业务 [11][12] - 公司对2025年前景保持乐观,预计Medicare Advantage利润率将改善100-200个基点,个人交易所和Medicaid业务也有望改善 [20][39][60] - 公司将继续推进生产力提升计划,预计2025年可实现超过5亿美元的利润增长 [81] - 公司对自身在降低药价、提高定价透明度等方面的能力和成果充满信心,将继续推动行业变革 [26][118][119][123][124][125] 其他重要信息 - 公司服务超过1.86亿人,消费者同时使用2种及以上公司产品的人数增加近250万,体现了公司一体化模式的价值 [13] - 公司已有13.8万Aetna医疗会员使用Caremark,较去年增长13% [13] - 公司数字客户达6000万,可通过数字渠道预约健康服务、配药和购买保健产品 [13] - 公司已关闭851家门店,预计今年底完成900家门店的关闭目标,剩余门店基本都是盈利的 [23][24] 问答环节重要的提问和回答 问题1 **Lisa Gill 提问** 对于2025年Medicare Advantage业务,公司是否已在投标中充分考虑了2023年下半年和2024年上半年观察到的更高利用率趋势? [63][64] **Tom Cowhey 回答** 公司在2025年投标中采取了谨慎的假设,充分考虑了2023年下半年和2024年上半年观察到的更高利用率趋势。公司相信通过调整福利等措施,可实现100-200个基点的利润率改善。即使未来利用率持续高于预期,公司也有信心在2025年实现目标利润率。[65][66][67] 问题2 **Justin Lake 提问** 公司是否仍有信心实现2025年的双位数盈利增长目标,主要的推动因素和潜在阻碍因素有哪些? [74][75] **Tom Cowhey 回答** 公司仍有信心实现2025年的双位数盈利增长目标。主要推动因素包括:医疗保险业务利润率改善、商业业务会员增长、健康服务和药品与消费者健康业务的持续强劲表现,以及公司启动的生产力提升计划。潜在阻碍因素包括医疗保险业务的一些压力,但公司相信通过各项措施可以得到缓解。公司将在稍后时间提供更详细的2025年指引。[76][77][78][79][80][81] 问题3 **Charles Rhyee 提问** 公司如何加强与国会的沟通,让他们更好地理解PBM在降低药价方面的作用,以及
CVS Health Stock Drops After Cutting Profit Forecast Again
Kiplinger.com· 2024-08-07 23:04
CVS Health (CVS) stock is in negative territory Wednesday after the pharmacy chain and healthcare benefits provider reported mixed results for its second quarter and slashed its full-year profit forecast.In the three months ended June 30, CVS said its revenue increased 2.6% year-over-year to $91.2 billion, driven by growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. However, its earnings per share (EPS) decreased 17.2% from the year-ago period to $1.83, primarily due to a decline ...
CVS cuts outlook, plans $2B cost-cutting effort
Fox Business· 2024-08-07 22:37
CVS Health on Wednesday cut its 2024 earnings outlook and announced its goal to cut $2 billion in costs through a multi-year productivity initiative as medical costs continue to rise. CVS reported that its adjusted earnings for the year will now be in the range of $6.40 to $6.65 per share, down from its earlier projection of at least $7 per share. This change reflects the "continued pressure in the Health Care Benefits segment," the company said.As part of its cost-cutting efforts, the retail pharmacy chain ...
Compared to Estimates, CVS Health (CVS) Q2 Earnings: A Look at Key Metrics
ZACKS· 2024-08-07 22:36
CVS Health (CVS) reported $91.23 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 2.6%. EPS of $1.83 for the same period compares to $2.21 a year ago.The reported revenue represents a surprise of -0.35% over the Zacks Consensus Estimate of $91.56 billion. With the consensus EPS estimate being $1.74, the EPS surprise was +5.17%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...
CVS Cuts Its Full-Year Profit Outlook, Again
Investopedia· 2024-08-07 22:26
KEY TAKEAWAYSCVS Health shares lost ground in early trading Wednesday after the pharmacy giant slashed its 2024 earnings guidance again amid increased medical costs.The company reported revenue for the second quarter that missed analysts' estimates, though earnings per share beat projections.CVS also announced the departure of the head of its Aetna unit. CVS Health (CVS) shares lost ground in early trading Wednesday after the pharmacy giant slashed its 2024 earnings guidance again amid increased medical cos ...
CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook
ZACKS· 2024-08-07 22:05
CVS Health Corporation (CVS) posted adjusted earnings per share (EPS) of $1.83 in the second quarter of 2024, down 17.2% year over year. However, the metric topped the Zacks Consensus Estimate by 5.2%. The adjusted EPS figure considers certain asset amortization costs, loss on assets held for sale and other adjustments.On a reported basis, the company’s GAAP earnings were $1.41, down 4.7% year over year.RevenuesRevenues in the second quarter rose 2.6% year over year to $91.23 billion. However, the top line ...
CVS Health (CVS) Beats Q2 Earnings Estimates
ZACKS· 2024-08-07 20:41
CVS Health (CVS) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.74 per share. This compares to earnings of $2.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.17%. A quarter ago, it was expected that this drugstore chain and pharmacy benefits manager would post earnings of $1.69 per share when it actually produced earnings of $1.31, delivering a surprise of -22.49%.Over the ...
CVS Health Corp shares under pressure after guidance downgrade
Proactiveinvestors NA· 2024-08-07 19:43
About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...
CVS Health(CVS) - 2024 Q2 - Quarterly Report
2024-08-07 18:35
财务业绩 - 公司总收入增长2.6%和3.1%,分别为三个月和六个月[242][249] - 医疗保健成本大幅增长27.9%和31.8%,分别为三个月和六个月[243][250] - 运营费用增长4.7%和6.0%,分别为三个月和六个月[245][250] - 营业利润下降5.8%和20.4%,分别为三个月和六个月[246][251] - 利息费用增加6.7%和13.6%,分别为三个月和六个月[247][252] - 所得税费用下降13.3%和26.4%,分别为三个月和六个月[248][253] - 净利润下降6.9%和28.6%,分别为三个月和六个月[243][251] - 公司总收入同比增长21.4%,达到324.75亿美元[278] - 医疗保险业务的医疗费用率(MBR)同比上升340个基点至89.6%[279] - 医疗保险业务的经营费用同比增长12.0%,但占总收入比重下降至13.7%[281] - 医疗保险业务的经调整经营利润同比下降39.1%,主要受到医疗利用率上升和Medicare Advantage评级下降的不利影响[282] - 公司总收入同比增长23.0%,达到647.11亿美元[283] - 医疗保险业务的医疗费用率(MBR)同比上升460个基点至90.0%[284] - 医疗保险业务的经营费用同比增长12.1%,但占总收入比重下降至13.6%[285] - 医疗保险业务的经调整经营利润同比下降50.4%,主要受到医疗利用率上升和Medicare Advantage评级下降的不利影响[286] - 总收入增加10.54亿美元,同比增长3.7%[308] - 调整后的营业利润下降1.7亿美元,同比下降12.0%,主要受到药房报销压力和前店销量下降的影响[311] - 总收入增加18.57亿美元,同比增长3.3%[314] - 调整后的营业利润下降1.27亿美元,同比下降5.0%,主要受到药房报销压力和前店销量下降的影响[318] - 总收入增加33.7%,主要由于净投资收益增加[324] - 调整后的经营亏损减少4.1%[326] - 总收入下降16.6%,主要由于净投资收益减少[327] - 调整后的经营亏损增加5.0%[329] 业务发展 - 收购Signify Health和Oak Street Health对运营产生影响[238][252] - 去年计提的重组费用和资产减值损失在本期不再发生[246][251] - 公司预计Medicare Advantage计划的会员人数将超出预期[254] - 医疗服务利用率,特别是在Medicare Advantage计划中,在2024年第二季度保持在较高水平,可能会对公司的医疗保健福利和医疗服务业务产生压力[255] - 公司的Medicaid业务正面临医疗成本压力,主要是由于成员重新认定后预期的疾病严重程度较高[255] - 公司的个人交易所业务受到风险调整计划的影响,公司需要根据其合格计划成员的风险水平相对于可比市场其他合格计划成员的平均风险水平来估计最终的风险调整应收或应付款[255] - 公司预计Cordavis、Oak Street Health和Signify Health等新业务将实现增长[255] - 公司将与客户分享更多从制药公司获得的回扣、费用和/或折扣,同时市场动态和监管变化也限制了公司向计划赞助商提供包含零售网络"差价"或"价差"的定价能力,这些趋势预计将持续[255] - GLP-1供应中断及其对产品组合的影响可能会影响公司向客户提供节省的能力,并可能影响公司的业绩[255] - 消费者支出管理和非必需消费支出下降,以及向价值、杂货和数字零售商的转移,可能会导致前店销售下降[255] - 医疗会员人数截至2024年6月30日为2700万人,较2024年3月31日增加20万人,主要反映了Medicare和Medicaid产品线的增长,包括2024年4月1日开始的Medicaid Oklahoma合同[290] - 医疗会员人数较2023年6月30日增加超过130万人,主要反映了Medicare和商业产品线的增长,部分被Medicaid产品线的下降所抵消,主要归因于2023年5月公共卫生紧急状态结束后Medicaid重新确定资格[290] - 2025年Medicare Advantage支付率的最终通知显示,预计Medicare Advantage行业的收入将平均下降0.16%,不包括CMS对Medicare Advantage风险评分趋势的估计[291] - 健康服务分部收入同比下降8.8%,主要由于之前宣布失去一个大客户以及持续的药房客户价格改善所致,部分被药品组合改善、公司医疗服务资产的贡献增加以及专科药房业务增长所抵消[295] - 健康服务分部经营费用同比增加6.9%,主要由于Oak Street Health的经营费用,包括已收购无形资产的摊销[296] - 健康服务分部经调整经营利润同比增加1.1%,主要由于采购经济性改善,部分被持续的药房客户价格改善和之前宣布失去一个大客户所抵消[297] - 处理的药房索赔量同比下降18.3%,反映了之前宣布失去一个大客户[298] - 健康服务分部的普通药品dispensing率保持相对稳定,在三个月和六个月期间均为88.2%和88.3%[299,304] - 药房同店销售增长9.1%,主要由于处方量增加6.5%和药品组合改善[309] - 前店同店销售下降4.0%,主要由于消费需求疲软和新冠检测试剂盒销量下降[309] - 处方量增加3.6%,主要由于使用量增加[312] - 普药占比上升至90.1%,主要由于新普药上市和公司鼓励使用普药[313] - 药房同店